Trial · NCT00656656
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
NCT00656656, Phase 2, Completed, University of Luebeck; results first posted 2016-12-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus. Trials, record NCT00656656. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00656656
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
- NCT number
- NCT00656656
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 23 participants, actual
- Lead sponsor
- University of Luebeck
- Conditions
- Pemphigus
- Interventions
- Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
- First posted
- 2008-04-11
- Last updated
- 2017-03-13
- Results first posted
- 2016-12-22
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients Achieving a Short- and Long-term Remission of Pemphigus | up to 43 months | Clinical remission was graded as partial remission on therapy, complete remission on therapy and complete remission off therapy, as described by Murell et al, J Am Acad Dermatol, 2008; 58:1043-6. |
| Secondary | Number of Patients Who Experienced Side-effects of Treatment | up to 43 months | Patients who experienced side-effects were counted. In addition, the nature and severity of side-effects were recorded. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients Achieving a Short- and Long-term Remission of Pemphigus | up to 43 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Patients Who Experienced Side-effects of Treatment | up to 43 months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients Achieving a Short- and Long-term Remission of Pemphigus | Immunoadsorption/Dexamethasone/Rituximab | 23 | Participants | ||
| Number of Patients Who Experienced Side-effects of Treatment | Immunoadsorption/Dexamethasone/Rituximab | 2 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Immunoadsorption/Dexamethasone/Rituximab | 23 | |
| Overall Study | COMPLETED | Immunoadsorption/Dexamethasone/Rituximab | 23 | |
| Overall Study | NOT COMPLETED | Immunoadsorption/Dexamethasone/Rituximab | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Sepsis | Infections and infestations | Immunoadsorption/Dexamethasone/Rituximab | 1 | 23 | |
| serious | extensive herpes simplex | Infections and infestations | Immunoadsorption/Dexamethasone/Rituximab | 1 | 23 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Immunoadsorption/Dexamethasone/Rituximab | ||
| Total, other adverse events | Immunoadsorption/Dexamethasone/Rituximab | 0 | 23 |
| Total, serious adverse events | Immunoadsorption/Dexamethasone/Rituximab | 2 | 23 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00656656
GET https://conductscience.org/api/trials/v1/NCT00656656/registered